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Abstract
Background: Ursodeoxycholic acid (UDCA) administration in intrahepatic cholestasis of pregnancy (ICP) induces bile acids
(BA) efflux from the foetal compartment, but the molecular basis of this transplacental transport is only partially defined.
Aim: To determine if placental breast cancer resistance protein (BCRP), able to transport BA, is regulated by UDCA in ICP.
Methods: 32 pregnant women with ICP (14 untreated, 34.965.17 years; 18 treated with UDCA - 25 mg/Kg/day, 32.764.62
years,) and 12 healthy controls (33.463.32 years) agreed to participate in the study. Placentas were obtained at delivery and
processed for membrane extraction. BCRP protein expression was evaluated by immunoblotting techniques and
chemiluminescence quantified with a luminograph measuring emitted photons; mRNA expression with real time PCR.
Statistical differences between groups were evaluated by ANOVA with Dunn’s Multiple Comparison test.
Results: BCRP was expressed only on the apical membrane of the syncytiotrophoblast. A significant difference was observed
among the three groups both for mRNA (ANOVA, p = 0.0074) and protein (ANOVA, p,0.0001) expression. BCRP expression
was similar in controls and in the untreated ICP group. UDCA induced a significant increase in placental BCRP mRNA and
protein expression compared to controls (350.76106.3 vs 100618.68% of controls, p,0.05 and 397.8656.02 vs
100611.44% of controls, p,0.001, respectively) and untreated ICP (90.29617.59% of controls, p,0.05 and 155.0613.87%,
p,0.01).
Conclusion: Our results confirm that BCRP is expressed only on the apical membrane of the syncytiotrophoblast and show
that ICP treatment with high dose UDCA significantly upregulates placental BCRP expression favouring BA efflux from the
foetal compartment.
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Introduction
Intrahepatic cholestasis of pregnancy (ICP), a liver disorder
unique to pregnancy, predominantly occurs during the third
trimester of gestation. ICP is characterized by pruritus and
biochemical alterations in liver tests which fully resolve after
delivery [1,2], and is associated with an increased risk of foetal
distress, preterm delivery and sudden intrauterine foetal death [3].
Given the substantial foetal risk, ICP is widely considered a serious
clinical problem [3].
Various hypothesis involving environmental, genetic and
hormonal factors have been investigated to elucidate the
pathogenesis of ICP. While no certain cause has been identified,
impaired bile acids (BA) metabolism leads to increased BA
accumulation in the foetal compartment [4]. Elevated maternal
BA levels affect placental transport, placental hormone production
and chorionic vessel constriction [5–8] and increase myometrial
sensitivity to oxytocin [7,9].
The placenta plays a major role in the pathophysiology of
adverse foetal effects because of its capacity to transport BA. This
capacity may somehow be regulated by ursodeoxycholic acid
(UDCA), the treatment of choice for ICP [3,10]. Previous studies
have shown that UDCA may improve bile acid transport across
the placenta and upregulate the expression of transporters
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localized on the apical side of the trophoblast membrane.
However, the classical transporters studied to date are not good
candidates for primary bile acid. The breast cancer resistance
protein (BCRP) has been reported to transport BA [11] but its
placental expression in ICP has not been evaluated. Therefore,
our study aimed to determine BCRP expression in ICP and its
regulation by UDCA administration.
Materials and Methods
Ethics Statement
All women gave verbal informed consent to the study that was
carried out according to the Declaration of Helsinki. All subjects
were older than 18 years and able to give informed consent. The
study was limited to the placenta which is routinely discarded as
waste material and there was no change to the current standard
medical and obstetric management of the patients. In addition, the
study involved no sensitive genetic data or investigations with
clinical consequences on the newborn or the mother. For these
reasons, ethics approval was not required according to the Italian
legislation (Law n.211, 24 June 2003, Directive 2001/20/CE).
However, a letter from the gastroenterologist to the gynaecologist/
obstetrician reporting patients’ verbal consent was attached to the
clinical records.
Patients
Thirty-two consecutive pregnant women with ICP were
enrolled in the study. A control group comprised 12 consecutive
healthy women with physiological pregnancies. The following
criteria were required for the diagnosis of ICP: elevated fasting
serum BAs (.10 mmol/L), elevated aminotransferases (.40 IU/L
for ALT and .37 IU/L for AST), and pruritus. Exclusion criteria
were infectious, metabolic or drug-related liver disease, and a
history of alcohol or drug abuse. Blood tests and abdominal
ultrasonography were performed to exclude obstructive cholestasis
and viral [anti-HCV antibodies [III generation enzyme-linked
immunosorbent assay (ELISA)], HBsAg, anti-Epstein–Barr virus,
anti-CMV, anti-HSV, anti-HIV], metabolic (blood cholesterol,
glucose, triglycerides and iron) or autoimmune (ANA, SMA,
AMA, p-ANCA and LKM) liver diseases.
Information on available treatments and their implications in
ICP was provided by the same doctor (GM) to all patients on
enrolment. Despite literature data suggesting that UDCA is the
first choice treatment in ICP, this indication is off-label in Italy.
Consequently, as the present study was not designed to evaluate
drug efficacy, patients were free to choose which arm to belong to
(treatment = group1/no treatment = group2). Therefore, treated
patients constituted group 1 while women with ICP who refused
UDCA treatment were included in the untreated group 2. Group
1 consisted of 18 ICP patients who received UDCA 25 mg/kg/
day; Group 2 consisted of 14 ICP patients who received only diet
and bed rest. Antihistaminics were allowed in case of intolerable
pruritus (leading to insomnia/restlessness).
Placenta Collection and Membrane Vesicle Preparation
Placentas were obtained from term delivery or caesarean section
(38–41 weeks) together with samples of cord and maternal blood.
All placentas were immediately washed with cold PBS, placed on
ice and processed for membrane separation or frozen in liquid
nitrogen. Apical membranes were prepared according to Grube
et al. [12] and the degree of enrichment in trophoblastic vesicles
was assessed by determination of alkaline phosphatase and ATP-
ase activity [13]. Briefly, pieces of placenta were homogenized
(UltraTurrax) for 2 min in lysis buffer (250 mM sucrose, 10 mM
Tris-HEPES pH 7, 4 mM EGTA, 5 mM EDTA) and centrifuged
at 9000 g for 10 min; the supernatant was centrifuged at 100000 g
for 35 min. The resulting pellet was resuspended in the lysis buffer
containing MgCl2 (final concentration 10 mM), stirred on ice for
10 min and then centrifuged at 2500 g for 15 min. The
supernatant, corresponding to the apical fraction and the pellet,
containing basolateral membranes were rehomogenized (Potter),
centrifuged at 100000 g per 35 min and the resulting pellets were
resuspended in 20–80 ml of buffer. The membrane protein
fractions were stored at –80uC until used.
Western Blot
Protein concentrations were determined according to the
method of Lowry et al. [14] and equal amounts of membrane
proteins (100 mg) were separated by standard SDS-PAGE
electrophoresis. Actin was used as an internal control (AC-40,
Sigma-Aldrich, St Louis, MO, USA), giving a constant signal in all
samples. After transfer onto nitrocellulose membrane, immuno-
blotting was performed with an overnight incubation with anti-
BCRP antibodies [anti ABCG2 (BXP21)sc-58222, anti ABCG2
(H70)sc-25821dil 1:100 in TBS-Tween, Santa Cruz Biotechnolo-
gy, Santa Cruz, CA, USA]. After a 1 h incubation at room
temperature with the peroxidase-conjugated secondary antibodies
(Envision antimouse IgG; K4001 and Envision antirabbit, K4003,
Dako, Glostrup, Denmark), chemiluminescent signals (ECL,
Amersham Pharmacia Biotech, Milan, Italy) were revealed by a
Luminometer (Molecular Light Imager, Berthold Technologies,
Bad Wildbad, Germany). The chemiluminescent signal was
quantified by Winlight 32 analysis software (Version 2.91,
Berthold Technologies).
Real-time PCR
Total RNA was extracted from 50–100 mg frozen placental
tissue using TrizolReagent (Invitrogen, Milan, Italy) according to
the manufacturer’s instructions. Purity of extracted RNA was
measured by the adsorbance ratio 260/280 nm (1.8–2.0) and its
integrity was controlled on 1% agarose gel. Two mg of RNA were
converted to first-strand cDNAs with the Superscript III reverse
transcriptase kit (Invitrogen, Life Technologies Europe BV,
Monza, Italy) according to the manufacturer’s instructions.
Real-time PCR was performed with the following primer and
probe sets (TaqMan Gene Expression Assays) diluted 1:20,
purchased from Applied Biosystems Italia (Monza, Italy):B-Actin
(Human beta actin, cat. N. 4333762F), BCRP (Hs01053786_m1).
Two ml of cDNA were added to TaqMan Universal Master Mix
(Applied Biosystems) and amplified in duplicate in an Applied
Biosystems 7000 real-time PCR cycler. Cycle conditions were
50uC for 2 min and 95uC for 10 min, then cycled to 95uC for 15 s
and 60uC for 1 min for 40 cycles. All samples were normalized to
B-actin expression levels and the relative quantification was
performed using the Ct method.
Statistics
Statistical differences between groups were evaluated by
ANOVA with Dunn’s Multiple Comparison test and the results
were expressed as mean 6 S.E. Chi-squared test and Mann-
Whitney test were used when appropriate.
Results
The groups were comparable with regard to age, parity and
type of delivery. As expected a significant difference was present
between controls and the cholestatic groups with regard to week of
delivery, serum bile acids and transaminase levels. No significant
UDCA Administration and BCRP Expression in ICP
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differences were observed between the treated and untreated
cholestatic groups (table 1).
Immunoblotting of apical and basolateral membranes con-
firmed that BCRP is expressed only on apical membranes of the
syncytiotrophoblast (figure 1). Then the evaluation of apical
membranes isolated from placentas collected from controls and
groups 1 and 2 showed that the BCRP protein was significantly
(p,0.0001) increased in group 2 (397.8656.02%) compared to
both group 1 and controls (155.0613.87% and 100.0611.44%,
respectively) (figure 2). Similarly, BCRP mRNA expression was
significantly (p = 0.0074) increased in group 2 (350.76106.3%) vs
group 1 and controls (90.29617.59% and 100.0618.68%,
respectively) (figure 3).
The type of delivery (vaginal or caesarean section) did not
significantly influence placental BCRP mRNA or protein levels
within the groups (see table 2).
Discussion
Our study shows that BCRP protein is upregulated in placentas
from ICP women receiving UDCA compared to untreated
patients and controls. We observed no significant difference in
BCRP levels between samples from vaginal or caesarean section
within each group suggesting that labour does not affect BCRP
expression. This observation is more consistent for group 1
because of comparable numbers of caesarean and vaginal
deliveries.
UDCA has been shown to improve bile acids (BA) transport
across the placenta both via ATP-dependent and independent
mechanisms [15]. The molecular basis of this transport remains
unsettled. In humans, the only ATP-dependent molecule found
modestly upregulated by UDCA in ICP is multidrug resistance
protein 2 (MRP2) [16]. Furthermore, MRP2 predominantly
transports bilirubin and to a minor extent sulphated BA [17,18],
Table 1. Baseline characteristics of the studied groups.
CONTROLS ICP ICP+UDCA p#
(N = 12) (N = 14) (N = 18)
Age 33.463.32 34.965.17 32.764.62 ns
Week of delivery 39.1761.4* 36.6461.80 35.5062.59 0.0003
Transaminases
GOT 23.066.54* 139.1674.81 135.46146.2 0.0001
GPT 16.6065.98* 233.2645.85 217.06238.6 0.0001
Bile acids
Cholic Acid 0.6260.76* 16.80617.52 20.53614.46 0.0002
Chenodeoxycholic
Acid
0.6360.66* 8.1568.55 12.7168.50 0.0002
Type of delivery
Vaginal 9 9 8 ns
Caesarean 3 5 10 ns
Parity
Primiparae 9 12 14 ns
Multiparae 3 2 4 ns
*vs ICP and ICP+UDCA.
doi:10.1371/journal.pone.0064101.t001
Figure 1. Western blotting of syncytiotrophoblast membranes
showing BCRP expression only on their apical side.
doi:10.1371/journal.pone.0064101.g001
Figure 2. Results of immunoblotting quantification showing
BCRP protein expression. A: an example of western blotting of BCRP
protein expression on the apical membranes of the syncytiotrophoblast
in the different groups under study. B: results of BCRP protein
quantification. *ANOVA – P,0.0001 (Dunn’s Test: ICP+UDCA vs CTRL,
P,0.001; ICP+UDCA vs ICP, P,0.01).
doi:10.1371/journal.pone.0064101.g002
Figure 3. Results of RT-PCR quantification showing BCRP
mRNA expression on the apical membranes of the syncytio-
trophoblast in the different groups under study. *ANOVA –
P = 0.0074 (Dunn’s Test: ICP+UDCA vs CTRL and vs ICP, P,0.05).
doi:10.1371/journal.pone.0064101.g003
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suggesting that other proteins are involved in BA transplacental
transport.
A few years ago, studies on BCRP-expressing bacteria showed
that BCRP can transport primary BA [11], but subsequent studies
in cells transfected with BCRP failed to show transport for
taurocholic acid and or taurolithocholate sulphate [19–21]. More
recently, in vitro and in vivo evidence in knockout mice suggests
that BCRP is able to transport BA across the epithelia that express
it including the placenta [22]. Recent findings in knockout mice
suggest that, despite a minimal/no role in the liver’s adaptive
response to cholestasis, BCRP might be implicated in solute export
in the kidney and intestine suggesting that its role in cholestasis
might be more prominent in extrahepatic tissues [23]. In this
regard, the placenta is a unique extrahepatic tissue that loses
expression of the main BA transporters (BSEP and NTCP) during
the course of gestation. Therefore, in the third trimester placenta,
specific BA transport is likely to be covered in part by other
transporters sharing a similar substrate specificity. ICP is typical of
the third trimester when oestrogen levels peak and favour
cholestasis while the putative BA transporters (BSEP and NTCP)
are not expressed in the human placenta despite the need for BA
transport.
In this setting, the presence of BCRP on the apical membrane of
the syncytiotrophoblast may suggest that the protein could
contribute to BA transport across the human placenta towards
maternal blood. We do not know whether the BCRP contribution
is tangible or not in humans, but literature evidence suggests that
this might be the case in mice [24].
Surprisingly, we did not observe a BCRP upregulation in
untreated patients compared to controls suggesting that placental
BCRP does not have an adaptive response in non obstructive
cholestasis in humans. Interestingly, BCRP was upregulated in
treated patients both at mRNA and protein levels, but the
mechanism by which UDCA induces a transcriptional upregula-
tion of BCRP is not straightforward. BCRP is regulated by various
endogenous and xenobiotic factors including hormones (proges-
terone and oestrogens) [25,26], highlighting the role of progester-
one and oestrogen regulation of BCRP in pregnancy. The effect of
oestradiol and progesterone has been studied in vitro with
contradictory results for both. Overall, the final effect of these
hormones on BCRP regulation seems to depend on their relative
levels and the expression of progesterone receptors B and A as well
as the ratio of the progesterone receptors (progesterone receptor
A/progesterone receptor B). BCRP is regulated by a number of
nuclear receptors including the peroxisome proliferator-activated
response (PPARc, hypoxia inducible factor (HIF-1), aryl hydro-
carbon receptor (AhR) and pregnane X receptor (PXR).
UDCA is not considered an effective ligand for nuclear
receptors and recent evidence suggests that FXR, CAR and
PXR are not significantly changed in human placenta during
cholestasis [27]. Therefore, whether UDCA can regulate BCRP
via activation of a signalling cascade or a modification of maternal
hormone levels has yet to be elucidated.
In conclusion, we showed that UDCA administration is
associated with a significant upregulation of human placental
BCRP supporting a role for BCRP in foetal protection. However,
the mechanism underlying this effect remains unknown.
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